Eli Lilly
LLY (NYSE)
Eli Lilly (LLY) stands out with remarkable growth, soaring 386.99% over the past five years, driven by its innovative diabetes and obesity treatments. Although it offers a modest dividend yield of 0.60%, the stock is backed by strong analyst recommendations, with a consensus rating of Buy and a 12-month price target range of $985 to $1,350. Given its strategic focus on expanding manufacturing capabilities and late-stage programs, Eli Lilly presents an attractive opportunity for investors seeking long-term growth.
Pros:
- Exceptional growth driven by key drugs
- Strong 5-year return
Cons:
- Low dividend yield
- Negative YTD return
Eli Lilly (LLY) may be suitable for long-term investors looking for growth potential in the healthcare sector, particularly those interested in innovative treatments for diabetes and obesity. While the modest dividend yield may not appeal to income-focused investors, the significant historical returns and strong analyst support indicate a promising outlook for those willing to embrace volatility in pursuit of capital appreciation.